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Objectives We sought to determine outcomes in patients with and without symptomatic cerebrovascular disease (sCVD)
undergoing heart transplantation. Second, we sought to determine factors associated with stroke in the periop-
erative period after heart transplantation.
Background sCVD is considered a relative contraindication to heart transplantation. Despite this concern, outcomes in pa-
tients with sCVD undergoing heart transplantation have not been well defined.
Methods Data on all single-organ heart transplants performed in the United States between April 1994 and December
2006 in patients age 40 years or older were analyzed. Survival analysis was performed to examine the effect of
sCVD on the combined outcome of stroke or death, stroke, death, and functional decline, adjusting for potential
confounding variables over long-term follow-up. In a separate analysis, predictors of perioperative stroke during
the transplant-related hospitalization were examined using multiple logistic regression.
Results There were 1,078 patients with and 16,765 patients without sCVD. The annualized rates of stroke or death
(11.5% vs. 7.8%; p  0.001), stroke (4% vs. 1.4%; p  0.001), death (8.9% vs. 7.4%; p  0.001), and functional
decline (3.7% vs. 3.0%; p  0.002) were higher in patients with sCVD than in patients without sCVD. In multivari-
able analysis, patients with sCVD were at increased risk of stroke or death (hazard ratio [HR]: 1.29; 95% confi-
dence interval [CI]: 1.17 to 1.42), stroke (HR: 2.24; 95% CI: 2.02 to 2.87), and functional decline (HR: 1.21; 95%
CI: 1.03 to 1.42) compared with those without sCVD. We did not identify a higher risk of death in patients with
sCVD (HR: 1.08; 95% CI: 0.98 to 1.20), compared with those without sCVD. sCVD, ventilator use, and ventricular
assist device use were the most important predictors of perioperative stroke.
Conclusions Patients with sCVD are at an increased risk of stroke and functional decline after transplantation independent of
other variables, but not death, during long-term follow-up. These results should assist programs in making in-
formed decisions in patients with sCVD who are undergoing evaluation for heart transplantation. (J Am Coll
Cardiol 2011;58:1036–41) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.038Heart transplantation is increasingly being performed in
patients older than 60 years of age and in those with
comorbidities (1). Cerebrovascular disease is considered a
relative contraindication to heart transplantation (2,3). Data
on outcomes associated with a number of pre-transplant
recipient comorbidities exist, but outcomes in patients with
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have not been evaluated (4).
Patients with symptomatic cerebrovascular disease
(sCVD), defined as previous transient ischemic attack
(TIA) or stroke, are at increased risk of further cerebrovas-
cular events (5,6). Patients with a history of TIA or stroke
are also at increased risk of death in the long term, with
See page 1042
60% of them dying at 10 years in 1 study (7). Heart
transplantation involves allocation of a scarce resource
among waitlisted candidates, and the benefits of im-
proved survival and quality of life depend on the degree of
recipient comorbidities. It is therefore important to
define outcomes in patients with cerebrovascular disease
undergoing heart transplantation.
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recipients to examine the long-term risk of stroke and death,
stroke, death, and functional decline, in patients with and without
sCVD. In separate analysis, we examined factors associated with
the risk of perioperative stroke during transplantation-related
hospitalization.
Methods
This analysis was based on data on all heart transplantations
performed in the United States between April 1, 1994, and
December 31, 2006, obtained from the Organ Procurement
and Transplant Network (OPTN), as of February 6, 2008.
We restricted the analysis to all first-time, single-organ
heart transplant recipients age 40 years or older. sCVD was
a yes/no variable on the transplantation candidate registra-
tion form and was intended to capture patients with a
previous cerebrovascular event or a TIA at registration.
Additional data were available on cerebrovascular events
between candidate registration and transplantation. We
defined sCVD as the presence of sCVD at candidate
registration or the occurrence of a cerebrovascular event
between candidate registration and transplantation. Of
the 20,227 eligible patients, 2,384 were excluded due to
missing data on sCVD at candidate registration or
missing data on cerebrovascular event between candidate
registration and transplantation. Data on stroke during
the transplant-related hospitalization and during
follow-up were collected at discharge and at follow-up
visits at 6 months, 1 year, and yearly thereafter. Data on
patients’ functional capacity were collected at transplant
recipient registration and at follow-up visits as described
previously. For patients who died during follow-up, the
date of death as recorded by the OPTN was used. For
patients who did not have a date of death recorded by the
OPTN but a date of death was available from the social
security death masterfile, included in the dataset from the
OPTN, this date was used. In the analysis examining
factors associated with perioperative stroke, patients
without data on sCVD were included, but those without
information on perioperative stroke were excluded. Of
20,227 patients, 1,092 were excluded due to missing data
on perioperative stroke. Perioperative stroke was defined
as stroke occurring anytime during the transplantation-
related hospitalization.
One of 2 different scales for functional status was used
for a given patient during the period under study in the
OPTN database. These scales are shown in Online Table
S1. We dichotomized functional status as either good or
reduced for the purpose of this study. A functional status
of “performs activities of daily living with no assistance”
or higher or “80%, normal activity with effort: some
symptoms of disease” or higher on these scales was
arbitrarily defined as good functional status. A functional
status of “performs activities of daily living with some
assistance” or lower or “70%, cares for self: unable to carryon normal activity or active
work” or lower was defined as
reduced functional status. A
transition from good functional
status to reduced functional
status as defined was considered
functional decline for time-to-
event analysis. Because patients
could have a temporary decline
in functional status, the defini-
tion of functional decline re-
quired that patients continue to
have reduced functional status
as defined for the rest of follow-
up, excluding those with return
to good functional status from
this definition of functional de-
cline. Patients who had reduced
or missing functional status at
transplantation and continued
to have reduced or missing
functional status throughout
follow-up were excluded.
Unadjusted annualized event rates (expressed as percent
per year) of combined outcome of stroke or death, stroke,
death, and functional decline in both groups were calculated
by dividing the number of events by person-years of
follow-up multiplied by 100. Unadjusted cumulative inci-
dence of outcomes at various time points were obtained by
the Kaplan-Meier product-limit method. For stroke or
functional decline that occurred between 2 follow-up visits,
this was assumed to have occurred at the midpoint of the
interval. Equality of survival curves was tested using log-
rank test.
Effect of sCVD on the risk of combined outcome of
stroke or death, stroke, death, and functional decline during
follow-up was examined using Weibull’s accelerated failure
time (AFT) model. Weibull’s AFT model was chosen for its
ability to handle interval censored data. Stroke and func-
tional status were interval censored in our data, being
collected only at follow-up visits. The models were adjusted
for donor and recipient age, sex combination, race, etiology
of cardiomyopathy (ischemic vs. nonischemic), drug-treated
hypertension (HTN), diabetes, drug-treated chronic ob-
structive pulmonary disease (COPD), dialysis status, wait-
list status, ventilator use, ventricular assist device (VAD)
use, creatinine, bilirubin, ischemia time, and year of trans-
plantation. Missing values of covariates were replaced by
their median or most common value for continuous and
categorical variables, respectively. Additionally, a Cox pro-
portional hazards (PHs) model was created for the outcome
of death and results compared with those of the Weibull
AFT model.
A multiple logistic regression model was used to examine
Abbreviations
and Acronyms
AFT  accelerated failure
time
CI  confidence interval
CM  cardiomyopathy
COPD  chronic
obstructive pulmonary
disease
HR  hazard ratio
HTN  hypertension
OPTN  Organ
Procurement
and Transplant Network
PH  proportional hazard
sCVD  symptomatic
cerebrovascular disease
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devicefactors associated with perioperative stroke. The model was
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outcomes previously described.
Statistical analysis was performed using SAS version
9.1.3 (SAS Institute Inc., Cary, North Carolina).
Results
There were 1,078 patients with and 16,765 patients without
sCVD as defined previously. Baseline characteristics of
patients with and without sCVD are shown in Table 1.
Patients with sCVD were more likely to be black; have
ischemic cardiomyopathy (CM), HTN, or diabetes; and be
on dialysis, ventilator, or VAD support compared with
patients without sCVD. They were more likely to be in
United Network for Organ Sharing 1A status at transplan-
tation, have longer ischemia time, and have been trans-
Baseline Characteristics inP ti nts With and Without sCVDTable 1 B seline Characteristics inPatients With and Without sCVD
Variable
No sCVD
(n  16,765)
sCVD
(n  1,078) p Value*
Recipient age, yrs 55.8 55.7 0.9
Donor age, yrs 31.5 31.7 0.5
Donor/recipient sex
Male/male 59.9 62.7 0.3
Female/male 18.8 18.0
Male/female 10.6 9.5
Female/female 10.7 9.8
Recipient race
White 80.5 78.9 0.001
Black 11.5 14.8
Other 8.1 6.2
Donor race
White 74.3 75.0 0.5
Black 11.4 10.2
Other 14.3 14.8
Ischemic CM 55.7 60.6 0.002
Drug-treated HTN 39.5 48.1 0.001
Diabetes 21.3 26.1 0.001
Drug-treated COPD 3.7 4.6 0.1
Dialysis 0.6 1.9 0.001
Waiting list status
Old status 1 25.9 25.5 0.001
Status 1A 19.8 31.1
Status 1B 24.5 24.8
Status 2 29.9 18.7
Ventilator use 2.6 4.7 0.001
VAD use 15.9 37.7 0.001
Creatinine, mg/dl 1.37 1.34 0.5
Total bilirubin, mg/dl 1.3 1.3 0.8
Ischemia time, h 3.1 3.2 0.001
Year of transplantation
1994–1997 29.0 23.6 0.001
1998–2000 25.3 27.3
2001–2003 23.4 26.2
2004–2006 22.3 23.0
Values are mean or %. *p value based on t test or chi-square test as appropriate.w
CM  cardiomyopathy; COPD  chronic obstructive pulmonary disease; HTN  hypertension;
sCVD  symptomatic cerebrovascular disease; VAD  ventricular assist device.planted in later years, compared with patients without
sCVD.
The follow-up in person-years for each of the outcomes,
the total number of events, the annualized event rates, and
percent cumulative incidence of events at various time
points are shown in Table 2. The number of events at each
time point and the number of patients remaining in the
analyses at each time point are provided in Online Table S2.
Stroke or death. The annual rate of stroke or death was
11.5% in patients with sCVD and 7.8% in patients without
sCVD (p  0.001) (Table 2). After multivariable adjust-
ment, risk of stroke or death was 29% higher in patients
with sCVD (hazard ratio [HR]: 1.29; 95% confidence
interval [CI]: 1.17 to 1.42) compared with those without
sCVD (Table 3). Other factors that were associated with
increased risk of stroke or death were recipient age, donor
age, male donor/female recipient combination, black recip-
ient race, ischemic CM, HTN, diabetes, COPD, dialysis,
creatinine, bilirubin, ischemia time, and ventilator or VAD
use at transplantation. Transplantations performed in later
years were associated with a decreased risk of stroke or
death.
Stroke. The annual rate of stroke was 4% in patients with
sCVD and 1.4% in patients without sCVD (p  0.001).
fter multivariable adjustment, risk of stroke was 2.41-fold
igher in patients with sCVD (HR: 2.41; 95% CI: 2.02 to
.87) compared with patients without sCVD. Other factors
hat were associated with increased risk of stroke were
ecipient age, male donor/female recipient combination,
schemic CM, diabetes, and ventilator or VAD use at
ransplantation. Later year of transplantation was associated
ith a decreased risk of stroke.
eath. The annual rate of death was 8.9% in patients with
CVD and 7.4% in patients without sCVD (p  0.001).
fter multivariable adjustment, we did not identify a higher
isk of death in patients with compared with those without
CVD (HR: 1.08; 95% CI: 0.98 to 1.20). Factors that were
ssociated with increased risk of death during follow-up
ere recipient and donor age, male donor/female recipient
ombination, black recipient race, ischemic CM, HTN,
iabetes, COPD, dialysis, creatinine, bilirubin, ischemia
ime, and ventilator or VAD use at transplantation.
Multivariable analysis for death was repeated using the
ox PHs model and gave results consistent with those of
he Weibull AFT model except that HRs for transplanta-
ion years 1998 to 2000, 2001 to 2003, and 2004 to 2006
compared with 1995 to 1997) were 0.95 (95% CI: 0.88 to
.02), 0.89 (95% CI: 0.81 to 0.98), and 0.82 (95% CI: 0.73
o 0.92). Complete results of the Cox PH model are
rovided in Online Table S3. Cox PHs model could not be
tted to data on stroke, stroke and death, and functional
ecline due to the interval-censored nature of these outcomes.
unctional decline. The annual rate of functional decline
as 3.7% in patients with sCVD and 3.0% in patients
ithout sCVD (p 0.002). After multivariable adjustment,
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August 30, 2011:1036–41 Cerebrovascular Disease and Heart Transplantationrisk of functional decline was 21% higher in patients with
sCVD (HR: 1.21; 95% CI: 1.03 to 1.42) compared with
patients without sCVD.
Outcomes in Patients With and Without sCVDTable 2 Outcomes in Patients With and Without sCVD
Before Discharge,
%
1 yr,
%
2 yrs,
%
5 yrs,
%
Stroke or death
No sCVD (n  16,765) 8.6* 15.4 19.5 29.8
sCVD (n  1,078) 15.1* 23.7 28.1 40.5
Stroke
No sCVD (n  16,765) 2.3 3.4 4.1 6.3
sCVD (n  1,078) 7.6 11.0 12.5 17.2
Death
No sCVD (n  16,765) 7.7* 13.5 17.5 27.2
sCVD (n  1,078) 11.0* 16.9 20.7 32.6
Functional decline
No sCVD (n  13,778) — 0.5 2.5 10.7
sCVD (n  826) — 0.5 3.6 12.9
*After excluding 99 without a discharge date. †Based on Kaplan-Meier analysis.
sCVD  symptomatic cerebrovascular disease.
Multivariable Adjusted Risk of Stroke or Death, Stroke, and DeathTable 3 Multivariable Adjusted Risk of Stroke or Death, Stroke
Variable Stroke or Death
HR* 95% CI p V
sCVD (vs. none) 1.29 1.17–1.42 0
Recipient age (per yr) 1.01 1.01–1.02 0
Donor age (per yr) 1.01 1.01–1.01 0
Donor/recipient sex (referent: male/male)
Female/male 1.06 0.99–1.13 0
Male/female 1.23 1.13–1.34 0
Female/female 1.06 0.98–1.16 0
Recipient race (referent: white)
Black 1.22 1.13–1.32 0
Other 1.02 0.93–1.13 0
Donor race (referent: white)
Black 1.03 0.95–1.11 0
Other 1.05 0.98–1.14 0
Ischemic CM (vs. nonischemic CM) 1.16 1.10–1.22 0
Drug-treated HTN 1.09 1.04–1.15 0
Diabetes 1.23 1.16–1.30 0
Drug-treated COPD 1.27 1.13–1.43 0
Dialysis 1.98 1.56–2.53 0
Waiting list status (referent: old status 1)
Status 1A 1.09 0.99–1.20 0
Status 1B 0.93 0.85–1.03 0
Status 2 0.95 0.89–1.02 0
Ventilator 1.63 1.44–1.86 0
VAD 1.27 1.19–1.37 0
Creatinine (per 1-mg/dl increase) 1.03 1.01–1.04 0
Total bilirubin (per 1-mg/dl increase) 1.01 1.01–1.02 0
Ischemia time (per 1-h increase) 1.06 1.04–1.09 0
Year of transplantation (referent: 1994–1997)
1998–2000 0.78 0.73–0.84 0
2001–2003 0.62 0.56–0.68 0
2004–2006 0.55 0.49–0.61 0*From Weibull accelerated failure time models.
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.Perioperative stroke. Of 19,135 transplant recipients, 505
(2.6%) had a perioperative stroke. The odds ratios for
perioperative stroke associated with various variables are
s,
Total Events
Follow-Up
(in Person-yrs)
Annualized Event Rate
(per 100) p Value†
5,999 76,765 7.8 0.001
480 4,169 11.5
1,050 76,765 1.4 0.001
166 4,168 4.0
5,962 80,764 7.4 0.001
423 4,774 8.9
2,212 73,417 3.0 0.002
158 4,216 3.7
e Study PopulationDeath in the Study Population
Stroke Death
HR* 95% CI p Value HR* 95% CI p Value
2.41 2.02–2.87 0.001 1.08 0.98–1.20 0.126
1.02 1.01–1.03 0.001 1.01 1.01–1.02 0.001
1.00 1.00–1.01 0.417 1.01 1.01–1.01 0.001
1.01 0.87–1.17 0.919 1.07 1.01–1.15 0.028
1.40 1.16–1.68 0.001 1.19 1.09–1.29 0.001
1.12 0.92–1.36 0.274 1.08 0.99–1.18 0.074
1.00 0.83–1.21 0.97 1.27 1.18–1.38 0.001
0.89 0.70–1.12 0.33 1.04 0.94–1.14 0.453
0.98 0.81–1.18 0.842 1.04 0.96–1.12 0.394
1.13 0.96–1.33 0.143 1.06 0.98–1.14 0.151
1.28 1.13–1.45 0.001 1.15 1.09–1.22 0.001
1.06 0.94–1.19 0.327 1.08 1.03–1.14 0.003
1.49 1.31–1.70 0.001 1.22 1.15–1.30 0.001
1.00 0.74–1.34 0.993 1.32 1.17–1.48 0.001
1.41 0.80–2.51 0.239 1.97 1.53–2.53 0.001
1.22 0.99–1.51 0.066 1.06 0.96–1.16 0.269
0.90 0.73–1.12 0.357 0.95 0.86–1.04 0.27
1.05 0.90–1.24 0.525 0.94 0.88–1.01 0.083
1.65 1.25–2.18 0.001 1.65 1.45–1.88 0.001
1.53 1.31–1.78 0.001 1.19 1.11–1.28 0.001
1.02 0.99–1.06 0.163 1.03 1.02–1.04 0.001
1.00 0.98–1.02 0.847 1.02 1.01–1.02 0.001
1.05 0.99–1.11 0.088 1.06 1.03–1.09 0.001
0.78 0.66–0.92 0.003 0.77 0.72–0.83 0.001
0.59 0.48–0.73 0.001 0.62 0.57–0.68 0.001
0.46 0.36–0.59 0.001 0.58 0.52–0.65 0.00110 yr
%
50.6
60.5
10.6
23.3
50.6
55.7
32.5
39.9in th, and
alue
.001
.001
.001
.077
.001
.146
.001
.642
.533
.160
.001
.001
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.001
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.155
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.001
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.001
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Cerebrovascular Disease and Heart Transplantation August 30, 2011:1036–41shown in Table 4. sCVD, recipient age, male donor/female
ecipient and female donor/female recipient combinations,
lack recipient race, diabetes, creatinine, ischemia time, and
entilator and VAD use were associated with increased risk
f perioperative stroke. Recent year of transplantation was
ssociated with a lower risk of perioperative stroke com-
ared with 1994 to 1997. A total of 31.9% of patients with
erioperative stroke died before discharge compared with
.9% of patients without perioperative stroke.
iscussion
he 2009 annual report of the International Society of
eart and Lung Transplantation mentions the risk of death
fter heart transplantation is not increased in patients with
erebrovascular disease but no further details were available
8). To the best of our knowledge, the current study is the
rst to comprehensively examine outcomes in patients with
CVD undergoing heart transplantation, with a large
Multivariable Adjusted Risk of PerioperativeStroke During Hear Tran plant Hos italizationTable 4 Multivariable Adjust d R sk of PerioperativeStroke During Heart Transplant Hospitalization
Variable Odds Ratio* 95% CI p Value
sCVD 2.84 2.21–3.65 0.001
Recipient age (per yr) 1.02 1.00–1.03 0.025
Donor age (per yr) 1.00 1.00–1.01 0.55
Donor/recipient sex
(referent: male/male)
Female/male 1.04 0.81–1.33 0.764
Male/female 1.59 1.20–2.11 0.001
Female/female 1.35 1.00–1.83 0.05
Recipient race (referent: white)
Black 0.72 0.52–1.00 0.048
Other 0.84 0.58–1.22 0.365
Donor race (referent: white)
Black 0.99 0.74–1.32 0.933
Other 1.07 0.82–1.39 0.631
Ischemic CM 1.19 0.98–1.46 0.077
Drug-treated HTN 1.07 0.89–1.29 0.469
Diabetes 1.29 1.04–1.59 0.02
Drug-treated COPD 0.82 0.49–1.36 0.432
Dialysis 1.04 0.45–2.43 0.926
Waiting list status (referent: old status 1)
Status 1A 1.29 0.91–1.81 0.15
Status 1B 0.89 0.63–1.28 0.542
Status 2 1.03 0.78–1.36 0.828
Ventilator 2.37 1.67–3.35 0.001
VAD 1.96 1.56–2.45 0.001
Creatinine (per 1 mg/dl) 1.05 1.00–1.10 0.032
Bilirubin (per 1 mg/dl) 1.00 0.98–1.03 0.765
Ischemia time (per 1 h) 1.13 1.03–1.23 0.007
Year of transplantation
(referent: 1994–1997)
1998–2000 0.75 0.56–0.99 0.04
2001–2003 0.70 0.50–0.98 0.036
2004–2006 0.59 0.41–0.84 0.004
*Adjusted for all variables in the table.
Abbreviations as in Tables 1 and 3.nough sample size to be able to provide reasonably preciseestimates of the effect of sCVD on stroke, death, and
functional decline after heart transplantation.
In our study, patients with sCVD had a higher unad-
justed annual rate of stroke, death, and functional decline
than patients without sCVD. However, patients with
sCVD had more comorbidities such as HTN, diabetes,
COPD, and renal failure requiring dialysis, which likely
contributed to worse outcomes. After adjustment for these
and other potential confounding factors, sCVD was associ-
ated with an 2.4-fold increase in risk of stroke and a 1.2-fold
increase in risk of functional decline. We did not identify a
higher risk of death in patients with sCVD.
A number of other factors previously known to be associated
with increased mortality after heart transplantation including
recipient age, donor age, ischemic CM, diabetes, creatinine,
bilirubin, ischemia time, dialysis status, and ventilator or VAD
use at the time of transplantation were also significant predic-
tors of mortality in our study (8). Our analyses also found the
following factors to be associated with increased mortality:
black recipient race, male donor/female recipient combination,
HTN, and COPD. The following factors were associated with
decreased mortality: United Network for Organ Sharing status 2
and later year of transplantation. Although the magnitude of
effect differed between the 2 models (Weibull AFT and Cox
PHs), both showed decreased mortality in recent years com-
pared with 1994 to 1997. The reason for the difference in
estimates of HRs obtained by the Weibull AFT and Cox PHs
models is not clear, but a conservative approach would be to
believe the estimates obtained by the Cox PHs model.
We did not find any large-scale study looking at risk factors
for stroke in the long-term after heart transplantation. In
addition to sCVD, our study identified the following factors to
be associated with stroke in the long term after heart trans-
plantation: recipient age, male donor/female recipient combi-
nation, ischemic CM, diabetes, and ventilator or VAD use.
Risk of stroke in the long term was lower in recent transplant
years compared with 1994 to 1997. Given the discrepancy in
HRs for death obtained by the Weibull AFT and Cox PHs
models, caution is advised in interpreting the HRs for stroke
with year of transplantation, which were derived using the
Weibull AFT model. Cox PHs model could not be fitted to
stroke due to the interval-censored nature of this outcome.
Perioperative stroke after heart transplantation is a devastat-
ing complication, with a 32% in-hospital mortality in this
study. There is considerable literature on the incidence, risk
factors, and prognosis of perioperative stroke after nontrans-
plantation cardiac surgery (i.e., coronary artery bypass graft
surgery and valve surgery), but none after heart transplantation
(9–21). The overall incidence of perioperative stroke after heart
transplantation was 2.6% in this study, similar in magnitude to
a stroke rate of 1.6% to 2.6% after nontransplantation cardiac
surgery (11,13–15). Similar to the findings in nontransplanta-
tion cardiac surgery, sCVD, recipient age, recipient female sex,
diabetes, and creatinine were significant predictors of periop-
erative stroke (9–16,19–22). In addition, our study identified
ischemia time and ventilator or VAD use to be associated with
m1041JACC Vol. 58, No. 10, 2011 Patlolla et al.
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stroke decreased significantly in recent years compared with
1994 to 1997.
Study limitations. sCVD was not explicitly defined and was
left to the discretion of the transplantation coordinator. It is
expected to include patients with a previous TIA or stroke, but
the lack of an explicit definition during data collection leaves
scope for misclassification. Data on the type of previous
cerebrovascular event, whether a TIA or ischemic or hemor-
rhagic stroke, that led to a patient being classified as having
sCVD and on imaging documentation of the presence of
extracranial vascular stenosis was not available. Therefore, a
proportion of patients classified as having sCVD could have
had a cardioembolic source of a TIA or stroke and not true
cerebrovascular disease. A proportion of patients with sCVD
could have had revascularization procedures such as carotid
endarterectomy or carotid stenting that could have decreased
the subsequent risk of stroke, but these data were not available.
Old status 1 was only reported through January 1999 and
status 1A and 1B were only reported from January 1999
onward. Therefore, the effect of status and year of transplan-
tation on outcomes should be interpreted with caution. Pa-
tients with sCVD who underwent transplantation are likely to
have been a select group who met the criteria of the transplan-
tation centers for a transplantation, and the outcomes noted in
this study may not be representative of all patients with
cerebrovascular disease screened for transplantation eligibility.
It is not known whether any of the worse outcomes noted in
the study are due to alternate donor hearts being given to
patients with sCVD. There has been considerable improve-
ment in VAD technology over the years, and the summary
estimate of the risk of stroke associated with VADs may not be
representative of the latest generation of VADs.
Conclusions
Patients with sCVD undergoing heart transplantation have
an increased risk of stroke and functional decline but not
death compared with those without sCVD. Although
sCVD by itself should not be an absolute contraindication
to heart transplantation, the worse outcomes should be
considered in the context of other comorbidities in deter-
mining transplantation candidacy.
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